Accepted for Publication: June 19, 2015.
Correction: This article was corrected online on February 29, 2016, to fix an error in Table 1.
Published Online: August 31, 2015. doi:10.1001/jamaneurol.2015.1806.
Study concept and design: Hellwig, Haghikia, Langer-Gould.
Acquisition, analysis, or interpretation of data: Hellwig, Rockhoff, Herbstritt, Borisow, Elias-Hamp, Menck, Gold, Langer-Gould.
Drafting of the manuscript: Hellwig, Langer-Gould.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Hellwig, Haghikia, Langer-Gould.
Obtained funding: Hellwig, Gold, Langer-Gould.
Administrative, technical, or material support: Hellwig, Herbstritt, Borisow, Elias-Hamp, Menck, Langer-Gould.
Study supervision: Hellwig, Langer-Gould.
Conflict of Interest Disclosures: Dr Hellwig is supported by the German Research Council (Deutsche Forschungsgemeinschaft [DFG]) and has received speaker honoraria from Biogen Idec, Teva Pharma, sanofi-aventis, Novartis Pharma, Bayer Healthcare, Genzyme, and Merck Serono. Dr Herbstritt has received speaker honoraria from Bayer Healthcare. Dr Haghikia is supported by the DFG. Dr Elias-Hamp has received speaker honoraria from Biogen Idec, Merck Serono, Bayer Healthcare, Almirall, Novartis Pharma, Teva Pharma, and Genzyme, and has received travel expense compensation from Bayer Healthcare, Merck Serono, and Novartis Pharma. Dr Gold has received payments for consultancy from Biogen Idec and Teva Pharma; and speaker honoraria and research grants from Biogen Idec Germany, Teva Pharma, sanofi-aventis, Novartis Pharma, Bayer Healthcare, and Merck Serono. Dr Langer-Gould is the site principal investigator for 2 industry-sponsored randomized clinical trials (Biogen Idec and Roche) and receives funding from the National Institutes of Health and the National Multiple Sclerosis Society. No other disclosures were reported.
Funding/Support: The finalization of this project was possible with a research grant from the German Research Foundation (He 6841/1/1). The German MS and pregnancy registry is partly supported by Bayer Healthcare, Biogen Idec, Merck Serono, Novartis Pharma, Teva Pharma, and Genzyme Pharmaceuticals (a sanofi-aventis company).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the patients for their participation and the German MS society, as well as all referring neurologists and nurses for their support.